P
ProHub
English 简体中文 繁體中文
BCG Medium Operations Cost Reduction

Biopharma Outsourcing

#Healthcare #Biopharma
ProHub Comment

This case requires structured cost-benefit analysis combining variable and fixed cost modeling with operational and regulatory risk assessment. The candidate must navigate the tension between significant cost savings ($8.875M) and non-financial risks (regulatory compliance, quality control, frozen shipment logistics), demonstrating both analytical rigor and strategic thinking.

Estimated Time 27 minutes
Difficulty Medium
Source Wharton
38 / 100
The client, Genome Bio, is a national biopharma manufacturer of the largest life-saving medicines for diseases and manufactures bio-materials in the USA. Due to the COVID pandemic, the costs of manufacturing these materials has significantly shot up and the client has been considering establishing manufacturing facilities in Mexico. Should the client outsource the supply of the biomaterial to Mexico facilities?

Clarifying Information

  1. Objective: To reduce costs of sourcing of the biomaterial and evaluate other benefits of establishing an alternate supply chain
  2. Business: The client owns and operates the facilities for biomaterial production and has a network of biomaterial production
  3. Customers: The biomaterials are manufactured and then sent distributed all over the US
Mock Interview
Interviewer

The client, Genome Bio, is a national biopharma manufacturer of the largest life-saving medicines for diseases and manufactures bio-materials in the USA. Due to the COVID pandemic, the costs of manufacturing these materials has significantly shot up and the client has been considering establishing manufacturing facilities in Mexico. Should the client outsource the supply of the biomaterial to Mexico facilities?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Genome Bio faces a post-COVID cost crisis and is evaluating outsourcing biomaterial manufacturing to Mexico. Through detailed cost modeling (variable costs saving $14/unit, fixed costs saving $3.75/unit), the analysis recommends proceeding with outsourcing while flagging critical regulatory and quality testing risks before full implementation.

Key Insights:

  1. Cost modeling must distinguish between variable costs (labor 40%, materials 55-80%, but shipping 180% of US) and fixed costs (facility setup, regulatory approval) to identify true savings drivers
  2. Quantifiable financial benefit ($8.875M savings on 500k units) serves as the primary recommendation pillar, but must be balanced against operational risks and regulatory uncertainties
  3. Risk mitigation strategy is essential: pilot quality testing and regulatory assessment must precede full facility establishment to validate assumptions about frozen biomaterial shipment compliance